Moreover, Aβ 42 and Aβ 40 levels increased over the 5 years, whereas the Aβ 42 /Aβ 40 ratio decreased (p <0.001). In conclusion, this study suggests that measurement of plasma Aβ should not be used clinically to predict dementia or AD. However, plasma Aβ 40 may possibly be regarded as a moderate risk marker comparable to other risk markers for AD such as firstdegree family history of dementia.
Introduction
Alzheimer's disease (AD) is the most common cause of dementia and is associated with large cost for the health care system. Development of disease-arresting or -modifying drugs for AD is currently ongoing. To be effective and prevent development of dementia, these novel therapeutic agents must be administered before extensive, irreversible neuropathologic damage has occurred. Hence, early or preclinical detection of individuals with ongoing neurodegenerative processes will be important in the future. For this purpose, biological markers must be identified, since changes in cognition are relatively late symptoms of these processes [1] .
One of the hallmark neuropathologic changes in AD is the occurrence of senile plaques. The major component in these plaques is amyloid-β (Aβ). This is a product of a proteolytic cleavage of the cell-membrane bound amyloid precursor protein (APP) by a specific set of secretases. Depending on the cleavage site, different isoforms of Aβ are produced. The most studied Aβ isoforms contain 40 amino acids (Aβ 40 ) or 42 amino acids (Aβ 42 ). Aβ 40 is most abundant whereas Aβ 42 is more prone to aggregate into oligomerers, fibrils and eventually into plaques. Aβ 40 is also found in plaques but is believed to aggregate first after the core of the plaque consisting primarily of Aβ 42 has developed [2, 3] .
As a biomarker for AD, the levels of Aβ 42 in the cerebrospinal fluid (CSF) discriminate and predict AD with high accuracy in patients with mild cognitive impairment (MCI) [4, 5] . CSF Aβ 42 levels have even correlated with future cognitive decline in cognitively unimpaired healthy individuals [6] [7] [8] . In contrast, CSF Aβ 40 levels have not shown the same high accuracy [2] . Measurement of Aβ in plasma instead of in CSF would be of value, because plasma is more easily obtained than CSF in the clinical practice. However, reports on the ability of plasma Aβ 40 and Aβ 42 levels to discriminate and predict AD in cohorts with MCI 4 have been contradictory [2, [9] [10] [11] . Similarly, mixed results have been reported in the ability of plasma Aβ levels to predict cognitive decline and AD development in older individuals without dementia [2, [9] [10] [11] .
In the present study we investigated whether plasma Aβ levels predicted development of dementia and AD in a population-based cohort of adults aged 70 years and older and without dementia. Plasma was analyzed for Aβ 40 and Aβ 42 in 730 healthy elderly who were subsequently followed for five years related to development of any type of dementia disorder.
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Materials and Methods
The study sample was derived from the Prospective Population Study of Women (PPSW) and from the Gerontological and Geriatric Population Studies (H70) in Gothenburg, Sweden [12] [13] [14] . Population samples were obtained from the Swedish Population Register, based on birth date, and included both persons living in private households and in institutions. The PPSW had its baseline examination in 1968-69 on a representative sample of women born in 1908, 1914, 1918, 1922, and 1930 Among these, 99 were lost due to other reasons (mainly refusal), leaving 567 (response rate 85%) for follow-up examination. Those not attending the follow-up examination (n=163), were traced in medical records for a diagnosis of dementia.
Compared to non-participants (n=461), those who participated (n=1018) in the study were less likely to die before January 2006 (13.4% vs. 20.4%, p<0.05), and were less often registered with a psychiatric diagnosis (9.6% vs. 16.7%, p<0.001) in the Swedish Hospital 6 Discharge register. In women, there were no significant differences in age (p=0.597) or hospital discharge diagnoses of dementia (3.3% vs. 5.0%, p=0.112). All men were 70 years old.
Informed consent was obtained from all participants and/or their relatives. The study was approved by the Ethics Committee for Medical Research at the University of Gothenburg.
Study examinations
Most participants were investigated at the geriatric outpatient clinic of Vasa Hospital in Gothenburg. Home visits were offered when needed. Examinations included comprehensive social, functional, somatic, neuropsychiatric and neuropsychological examinations, and close informant interviews. Neuropsychiatric examinations and close informant interviews were performed by experienced psychiatric research nurses. The examinations and interviews were semi-structured and included psychiatric symptoms and signs, mental and cognitive functioning, behaviour, and activities of daily living, as described previously [15] . Episodic memory was estimated with a ten word immediate and delayed recall test with an intermediate distraction task.
The somatic examinations included systolic and diastolic blood pressure (SBP/DBP) in the seated position after 5 minutes rest, body height (nearest cm) and weight (nearest 0.1 kg), body-mass-index (BMI) determination (kg/m 2 ), electrocardiogram (ECG) and fasting blood samples analyzed for determination of Aβ levels, APOE genotype, glucose, and cholesterol.
The participants were additionally surveyed regarding educational level (less or more than basic = 6-7 years), medication use, and history of myocardial infarction, diabetes mellitus and stroke/TIA. Antiplateletes treatment was categorized as use of acetylsalicylic acid or clopidogrel.
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Dementia diagnoses
Dementia at the examinations was diagnosed according to the Diagnostic and Statistical
Manual of Mental Disorders, Third edition, revised (DSM-III-R) criteria [16] by neuropsychiatrists at consensus meetings using information from neuropsychiatric examinations and close informant interviews. AD was diagnosed according to NINCDS-ADRDA-criteria [17] and Vascular dementia (VaD) according to NINDS-AIREN criteria [18] .
For those who were lost to follow-up in 2005-06, psychiatrists examined hospital medical records, the Swedish Hospital Discharge Register, and death certificates for information regarding dementia diagnoses. Information regarding dementia diagnoses was available for all participants since almost all people in Sweden have access to public health services and therefore have equal chances to have medical records, or being in the hospital discharge register.
Analysis of plasma
At baseline and follow-up blood samples were drawn by venipuncture in the morning after an overnight fast. For plasma collection, blood was drawn into tubes containing EDTA as anticoagulant. After centrifugation, plasma was aliquoted into polypropylene tubes and stored at −80 °C pending biochemical analyses, without being thawn and re-frozen. Quantification of Aβ 40 and Aβ 42 in plasma was performed using Luminex xMAP technology and the INNO-BIA plasma Aβ forms assays (Innogenetics, Ghent, Belgium) as previously described [19] .
Plasma Aβ levels are presented as ng/L.
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Serum cholesterol levels were measured at the Clinical Chemistry Laboratory at Sahlgrenska University Hospital according to clinical practice and measured in mmol/l.
Statistical analyses
Two primary analysis strategies were pursued: 1) baseline, cross-sectional among all study participants; and 2) prospective analyses predicting the odds of dementia from baseline Aβ measures.
Baseline, cross-sectional analyses: Means and standard deviations were calculated for all quantitative variables (e.g., age, MMSE score, Aβ levels, BMI, etc. 
Results
Of 730 participants without dementia at baseline, 53 ( Participants who developed dementia during follow-up did not differ in baseline plasma Aβ 40 or Aβ 42 levels compared to those remaining without dementia (Table 1) . This was also observed in analyses by dementia subtype (Table 1) . However, as shown in 
Discussion
In this study we found that individuals without dementia and with plasma Aβ 40 levels above the median level for the population had a slightly increased risk to develop dementia and AD dementia over a 5-year period. However, the plasma levels of Aβ 42 and Aβ 42 /Aβ 40 ratio were not found to be associated with future development of dementia.
The ability of plasma Aβ 40 and Aβ 42 levels in population-based samples of older adults to predict dementia has been studied previously, and the results are conflicting. Most of the population-based studies align with our findings suggesting that higher plasma Aβ 40 levels are related to an increased risk of developing AD dementia, and in some cases, an increased risk of VaD [20] [21] [22] [23] . However, several other population-based studies report no relationship between plasma Aβ 40 and AD dementia [24] [25] [26] or between plasma Aβ 40 and cognitive decline [27] or that decreased plasma Aβ 40 levels are related to an increased risk of AD [28] .
Similarly, studies investigating the utility of plasma Aβ 40 to discriminate individuals with AD dementia from other dementia subtypes report conflicting findings, where both higher levels [21] and lower levels [28, 29] of plasma Aβ 40 levels have been associated with AD dementia, as well as no difference in Aβ 40 levels from other dementia subtypes [19, [30] [31] [32] . Conflicting patterns are also observed for plasma Aβ 42 [19, 22, [24] [25] [26] [27] [28] 31] and plasma Aβ 42 /Aβ 40 ratio, [21, 22, 25, 26, 30, 32] which in our study did not affect the risk for development of dementia or AD dementia. Additionally, it is evident in all studies that there is substantial overlap in plasma Aβ 40 and Aβ 42 levels between diagnostic groups [9, 11, 32] . The contradictory results and the substantial overlap between diagnostic groups together with the moderately increased odds ratio found in the present study strongly suggest that plasma Aβ 40 and Aβ 42 are not diagnostic or predictive markers for AD that can be used in a clinical setting. Instead, Aβ 40 could possibly be regarded as a rather weak risk marker, which has also been proposed by 13 others [10, 11, 20] . The odds ratio of plasma Aβ 40 for future AD is similar to that reported for first-degree family history of dementia [33, 34] .
Several studies have shown that plasma Aβ levels do not correlate to amount of cerebral amyloid depositions [35] [36] [37] . Thus, plasma Aβ differs from CSF Aβ 42 because there are studies showing a correlation between CSF amyloid and brain amyloid load [36, 38] .
Similarly, the association between Aβ 42 in CSF and future development of AD is stronger than that presented for plasma Aβs [2, 4, 9] . A possible explanation is that plasma Aβ is produced by many different cells types outside the central nervous system [2, 11, 39] and several studies have shown that plasma levels of Aβ do not correlate to the levels found in CSF [19, [35] [36] [37] . It has been proposed that plasma Aβ levels reflect Aβ clearance rather than cerebral Aβ load and might associate more strongly with microvascular dysfunction than CSF concentrations [11] . Additional support for this hypothesis are observed relationships between plasma Aβ levels and amount of both lacunar infarcts and white matter lesions as well as with atherosclerotic vessels. This could also explain observations that plasma Aβ 40 levels are associated with future development of VaD in addition to AD [21, [39] [40] [41] .
While there are numerous strengths of this study, there are also limitations. First, participants in this study were all without dementia at baseline and re-evaluated after 5 years. This followup period is short, and there is a risk that some of the cases in the cognitively stable group are indeed affected by prodromal dementia disorders and will develop dementia after more than 5 years. Hence, the OR presented could be underestimated, given the assumption that plasma Aβ 40 is also changed in this asymptomatic subgroup. Clinical follow-up periods of more than five years are needed to answer this question. Second, no evaluation in regard to MCI diagnosis was available for the individuals, which could further increase the risk of underestimating the prevalence of prodromal dementia disorders. However, no relationship between MMSE score or episodic memory performance at follow-up and the studied plasma
14
Aβ levels could be observed in the group who did not develop dementia. Third, not all participants (22 %) were clinically evaluated at follow-up. For these individuals the follow-up dementia diagnosis was based on a medical record review and information from the Swedish Hospital Discharge Register. The risk of misclassification is greater in this subgroup without neuropsychiatric examination at follow-up. However, conducting the analyses separately for those participating in the neuropsychiatric examination (78 %) shows similar results, as those obtained using all participants in the study. Nevertheless, in comparison to the other plasma amyloid studies using community dwelling population [20-22, 24-28, 30] , this study could include a relatively high percentage (49 %) of individuals from the original cohort. Moreover, quite few individuals were lost during follow-up as journal records were used in addition to the clinical evaluation within the study.
Conclusions
Our data suggest that measurement of plasma Aβ is not clinically useful to predict AD or dementia. However, plasma Aβ 40 may possibly be regarded as a moderate risk marker comparable to other risk markers for AD such as first degree family history of dementia. 
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Figure Legends Participant flow-chart with follow-up diagnosis presented for the entire group as well as specified for the individuals with full cognitive follow-up evaluation and for the individuals with only medical journal record follow-up.
